Abstract
Schlafen-11 (SLFN-11) was recently identified as a predictive marker of platinum-based drugs. In Japan, neoadjuvant chemotherapy, consists of 5-fluorouracil and cisplatin (NAC-FP), followed by surgery is the standard therapy for patients (pts) with resectable esophageal squamous cell carcinoma (ESCC). However, the correlation between SLFN-11 expression level and prognosis in ESCC pts treated with NAC-FP is unclear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
